| abstract |
The invention relates to a composition for a pharmaceutical solid drug form, which comprises baricitinib hydrobromide in the amount of 2.5 % w/w or more, relative to the total weight of the composition, a filler, and at least one additional pharmaceutically acceptable excipient. Such composition has a number of technological advantages. n The additional pharmaceutically acceptable excipients may include disintegrants and lubricants. |